{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:11:23Z","timestamp":1791202283359,"version":"4.2.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    This study compared different doublet and triplet therapies for efficacy and safety in metastatic hormone-sensitive prostate cancer (mHSPC). PubMed, EMBASE, and the Cochrane Library were comprehensively searched for eligible randomized controlled trials (RCTs) published from inception to October 2023. Interventions included abiraterone, apalutamide, enzalutamide, docetaxel, darolutamide, and androgen deprivation therapy (ADT), either as doublet or triplet therapies. The outcomes examined were overall survival (OS), progression-free survival (PFS), castration-resistant prostate cancer (CRPC)-free survival, time to symptomatic skeletal event (SSE), and toxicity. The surface under the cumulative ranking curve (SUCRA) was determined to identify the preferred treatments. Ten RCTs were included. The combination of darolutamide, docetaxel, and ADT had the highest SUCRA of 84.3 for OS, followed by combined abiraterone, docetaxel, and ADT (SUCRA = 71.6). The highest SUCRAs for PFS were observed for triplet therapies (abiraterone, docetaxel, and ADT [SUCRA = 74.9], followed by enzalutamide, docetaxel, and ADT [SUCRA = 74.3]) and other androgen receptor axis-targeted therapy-based doublet therapies (SUCRAs: 26.5\u201359.3). Darolutamide, docetaxel, and ADT had the highest SUCRAs,\n                    <jats:italic toggle=\"yes\">i.e<\/jats:italic>\n                    ., 80.8 and 84.0 regarding CRPC-free survival and time to SSE, respectively. Regarding Grade &gt;3 adverse events (AEs), the SUCRAs of triplet therapies (SUCRAs: 14.8\u201331.5) were similar to that of docetaxel and ADT (SUCRA = 39.5). Three studies had a low risk of bias in all categories; the remaining studies had at least an unclear risk of bias in at least one category. Triplet therapy demonstrated potentially enhanced effectiveness than doublet therapy in mHSPC, with acceptable safety concerns. Darolutamide might be the optimal option for triplet therapy in combination with docetaxel and ADT.\n                  <\/jats:p>","DOI":"10.4103\/aja20242","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:35Z","timestamp":1712880035000},"page":"402-408","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Network meta-analysis of combination strategies in metastatic hormone-sensitive prostate cancer"],"prefix":"10.4103","volume":"26","author":[{"given":"Shan-Shan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jie","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Long","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-He","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Wei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,12]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1016\/j.cell.2022.06.018","article-title":"Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy","volume":"185","author":"Luoma","year":"2022","journal-title":"Cell"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"659135","DOI":"10.3389\/fonc.2021.659135","article-title":"Impact of time to castration resistance on survival in metastatic hormone sensitive prostate cancer patients in the era of combination therapies","volume":"11","author":"Wenzel","year":"2021","journal-title":"Front Oncol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1200\/JCO.20.03256","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer:ASCO Guideline update","volume":"39","author":"Virgo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"R8-20240829","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3747\/co.v17i0.709","article-title":"Androgen deprivation therapy for prostate cancer \u2013review of indications in 2010","volume":"17","author":"Quon","year":"2010","journal-title":"Curr Oncol"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11523-018-0611-0","article-title":"Therapy of advanced prostate cancer:targeting the androgen receptor axis in earlier lines of treatment","volume":"13","author":"Shah","year":"2018","journal-title":"Target Oncol"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE):survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","article-title":"Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer:a systematic review and network meta-analysis","volume":"77","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1):a multicentre, open-label, randomised, phase 3 study with a 2 \u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"102441","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.euo.2022.06.003","article-title":"Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer:a network meta-analysis","volume":"5","author":"Roy","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"57","DOI":"10.5152\/tao.2019.4058","article-title":"A guide for systematic reviews:PRISMA","volume":"57","author":"Selcuk","year":"2019","journal-title":"Turk Arch Otorhinolaryngol"},{"key":"R23-20240829","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pedhc.2021.04.011","article-title":"PRISMA 2020:an update","volume":"35","author":"Swartz","year":"2021","journal-title":"J Pediatr Health Care"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15):a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1470-2045(23)00148-1","article-title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy:final results from two randomised phase 3 trials of the STAMPEDE platform protocol","volume":"24","author":"Attard","year":"2023","journal-title":"Lancet Oncol"},{"key":"R27-20240829","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET):an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-04-2140","article-title":"Timing is everything:preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer","volume":"11","author":"Eigl","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/pcan.2016.10","article-title":"Chemotherapy for metastatic castrate-sensitive prostate cancer","volume":"19","author":"Miller","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-05-1388","article-title":"Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice","volume":"12","author":"Tang","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R31-20240829","first-page":"113258","article-title":"Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC):a subpopulation analysis of the phase 3 ARASENS study","volume":"192","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.euo.2022.04.007","article-title":"Treatments for metastatic hormone-sensitive prostate cancer:systematic review, network meta-analysis, and benefit-harm assessment","volume":"5","author":"Menges","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"R35-20240829","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer:impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"R36-20240829","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer:long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"R37-20240829","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2017.10.002","article-title":"Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer:a systematic review and network meta-analysis","volume":"73","author":"Wallis","year":"2018","journal-title":"Eur Urol"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja20242","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:32:22Z","timestamp":1787769142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja20242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/aja20242","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,12]]},"assertion":[{"value":"2023-06-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}